Solara Active Pharma Sciences Limited — Board Meeting, 21-10-2024: Outcome of Board Meeting

Solara Active Pharma Sciences announced its unaudited financial results for Q2 FY25, reporting revenues of INR 3,472 million, down 5% QoQ but showing strong growth in EBITDA, which rose 46% QoQ to INR 616 million. Gross margins improved significantly to 50.5%, marking a notable recovery. The Company aims for FY25 revenues of approximately INR 15,000 million with EBITDA projected between INR 2,300 and INR 2,600 million, while reducing gross debt from INR 9,994 million to INR 8,195 million.